WE CLAIM:

1. A compound having Formula (I):



(I)

or a pharmaceutically acceptable salt or protected version thereof,

wherein:

R^1 is selected from: -H, $-CH_3$, $-CHF_2$, $-CF_3$, -F, -Br, -Cl, -OH, $-OCH_3$, $-OCF_3$ and $-NH_2$, and

R^2 is selected from: -H, $-CH_3$, $-CF_3$, -F, -Br, -Cl, -OH, $-OCH_3$ and $-OCF_3$,

and wherein:

when R^1 is $-NH_2$, then R is R^3 or R^4, and when R^1 is other than $-NH_2$, then R is R^4;

R^3 is selected from: -H, $-C_1$-C_6 alkyl, $-C_3$-C_8 cycloalkyl, $-(C_1$-C_6 alkyl)-O-R^5,  , $-CO_2R^8$, -aryl, -heteroaryl and $-(C_1$-C_6 alkyl)-aryl;

R^4 is selected from:  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , and  ;

R^5 is selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl, -aryl and –(C_1-C_6 alkyl)-aryl;

R^6 and R^7 are each independently selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -(C_1-C_6 alkyl)-O-R^5, -C_3-C_8 heterocycloalkyl and -C(O)R^{17};

R^8 is selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

each R^9 is independently selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

each R^{10} is independently selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -$NR^{14}R^{14'}$, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

each $R^{10'}$ is independently selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl, and –(C_1-C_6 alkyl)-aryl;

R^{11} is selected from: -H and -C_1-C_6 alkyl;

R^{12} is selected from: -H, -C_1-C_6 alkyl, -CO_2R^8, -aryl, -heteroaryl,–(C_1-C_6 alkyl)-aryl, -$S(O)_2R^{16}$ and  ;

R^{13} is selected from: -H and -C_1-C_6 alkyl;

R^{14} and $R^{14'}$ are each independently selected from: -H, C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

R^{16} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{17} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -C_3-C_8 heterocycloalkyl, –(C_1-C_6 alkyl)-C_3-C_8 heterocycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{18} and R^{19} taken together with the N atom to which they are bonded form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from: halogen, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -(C_1-C_6 alkyl)-O-R^5;

R^{24}, R^{25} and R^{26} are each -C_1-C_6 alkyl;

X^a and X^b are each independently selected from: NH, O and S, and

X^c is selected from; O, S and $S(O)_2$,

with the proviso that the compound is other than (S)-9-amino-11-butyl-4-ethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione.

2. The compound according to claim 1, wherein R^1 is NH_2, and R is R^3 or R^4.

3. The compound according to claim 2, wherein R^2 is other than -H.

4. The compound according to claim 1, wherein R^1 is selected from: -H, $-CH_3$, $-CHF_2$, $-CF_3$, -F, -Br, -Cl, -OH, $-OCH_3$ and $-OCF_3$, and R is R^4.

5. The compound according to claim 1 or 4, wherein R^2 is selected from: -H, $-CH_3$, $-CF_3$, -F, -Cl, $-OCH_3$ and $-OCF_3$.

6. The compound according to any one of claims 1 to 4, wherein R^4 is selected from:



7. The compound according to claim 1 having Formula (II):



(II)

or a pharmaceutically acceptable salt or protected version thereof,

wherein:

R^2 is selected from: -H, $-CH_3$, $-CF_3$, -F, -Br, -Cl, -OH, $-OCH_3$ and $-OCF_3$;

R^{20} is selected from: -H, $-C_1$-C_6 alkyl, $-C_3$-C_8 cycloalkyl, -(C_1-C_6 alkyl)-O-R^5,

 , $-CO_2R^8$, -aryl, -heteroaryl,–(C_1-C_6 alkyl)-aryl,  ,  , 



R^5 is selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^6 and R^7 are each independently selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -(C_1-C_6 alkyl)-O-R^5, -C_3-C_8 heterocycloalkyl and -C(O)R^{17};

R^8 is selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

each R^9 is independently selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

each R^{10} is independently selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -$NR^{14}R^{14'}$, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

each $R^{10'}$ is independently selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{11} is selected from: -H and -C_1-C_6 alkyl;

R^{12} is selected from: -H, -C_1-C_6 alkyl, -CO_2R^8, -aryl, -heteroaryl, –(C_1-C_6 alkyl)-aryl, -$S(O)_2R^{16}$ and  ;

R^{13} is selected from: -H and -C_1-C_6 alkyl;

R^{14} and $R^{14'}$ are each independently selected from: -H, C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

R^{16} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{17} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -C_3-C_8 heterocycloalkyl, –(C_1-C_6 alkyl)-C_3-C_8 heterocycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{18} and R^{19} taken together with the N atom to which they are bonded form a 4-, 5-, 6-, or 7-membered ring having 0 to 3 substituents selected from: halogen, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -(C_1-C_6 alkyl)-O-R^5;

R^{24}, R^{25} and R^{26} are each -C_1-C_6 alkyl;

X^a and X^b are each independently selected from: NH, O and S, and

X^c is selected from: O, S and $S(O)_2$.

8. The compound according to claim 7, wherein R^2 is selected from: -CH_3, -CF_3, -F, -Br, -Cl, -OH, -OCH_3 and -OCF_3.

9. The compound according to claim 7, wherein R^2 is selected from: -CH_3, -CF_3, -F, -Cl, -OCH_3 and -OCF_3.

10. The compound according to any one of claims 7 to 9, wherein R^{20} is selected from: -H, -C_1-C_6 alkyl, -(C_1-C_6 alkyl)-O-R^5,  , –(C_1-C_6 alkyl)-aryl,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , and  .

11. The compound according to any one of claims 7 to 9, wherein R^{20} is selected from: -H, -C_1-C_6 alkyl, -(C_1-C_6 alkyl)-O-R^5,  , –(C_1-C_6 alkyl)-aryl,  ,  ,  ,  ,  ,  ,  ,  , and  .

12. The compound according to any one of claims 7 to 9, wherein R^{20} is selected from: -H, -C_1-C_6 alkyl, -(C_1-C_6 alkyl)-O-R^5,  ,  , and .

13. The compound according to claim 7 having Formula (IIa):



(IIa)

wherein: R^{20}, R^5, R^6, R^7, R^8, R^9, R^{10}, $R^{10'}$, R^{11}, R^{12}, R^{13}, R^{14}, $R^{14'}$, R^{16}, R^{17}, R^{18}, R^{19}, X^a, X^b and X^c are as defined in claim 7.

14. The compound according to claim 13, wherein R^{20} is selected from: -H, -C_1-C_6 alkyl, -(C_1-C_6 alkyl)-O-R^5,  ,  , and .

15. The compound according to claim 1 having Formula (III):



(III)

or a pharmaceutically acceptable salt or protected version thereof,

wherein:

R^2 is selected from: -H, $-CH_3$, $-CF_3$, -F, -Br, -Cl, -OH, $-OCH_3$ and $-OCF_3$;

R^{15} is selected from: -H, $-CH_3$, $-CHF_2$, $-CF_3$, -F, -Br, -Cl, -OH, $-OCH_3$ and $-OCF_3$;

R^4 is selected from: 

and  ;

R^5 is selected from: -H, $-C_1$-C_6 alkyl, $-C_3$-C_8 cycloalkyl, -aryl, -heteroaryl and $-(C_1$-C_6 alkyl)-aryl;

R^8 is selected from: -H, $-C_1$-C_6 alkyl, $-C_3$-C_8 cycloalkyl and $-C_3$-C_8 heterocycloalkyl;

each R^9 is independently selected from: -H, $-C_1$-C_6 alkyl, $-C_3$-C_8 cycloalkyl, -aryl, -heteroaryl and $-(C_1$-C_6 alkyl)-aryl;

each R^{10} is independently selected from: $-C_1$-C_6 alkyl, $-C_3$-C_8 cycloalkyl, $-NR^{14}R^{14'}$, -aryl, -heteroaryl and $-(C_1$-C_6 alkyl)-aryl;

each $R^{10'}$ is independently selected from: -H, $-C_1$-C_6 alkyl, $-C_3$-C_8 cycloalkyl, -aryl, -heteroaryl and $-(C_1$-C_6 alkyl)-aryl;

R^{11} is selected from: -H and $-C_1$-C_6 alkyl;

R^{12} is selected from: -H, -C_1-C_6 alkyl, -CO_2R^8, -aryl, -heteroaryl, –(C_1-C_6 alkyl)-aryl, -$S(O)_2R^{16}$ and  ;

R^{13} is selected from: -H and -C_1-C_6 alkyl;

R^{14} and $R^{14'}$ are each independently selected from: -H, C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

R^{16} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{18} and R^{19} taken together with the N atom to which they are bonded form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from: halogen, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -(C_1-C_6 alkyl)-O-R^5;

R^{24}, R^{25} and R^{26} are each -C_1-C_6 alkyl;

X^a and X^b are each independently selected from: NH, O and S, and

X^c is selected from: O, S and $S(O)_2$.

16. The compound according to claim 15, wherein R^2 is selected from: -H, -F, -Br and -Cl.

17. The compound according to claim 15, wherein R^{15} is selected from: -CH_3, -CF_3, -OCH_3 and -OCF_3.

18. The compound according to claim 15, wherein R^{15} is -CH_3 or -OCH_3.

19. The compound according to any one of claims 15 to 18, wherein R^4 is selected from: 

20. The compound according to claim 15 having Formula (IIIa) or (IIIb):



(IIIa)



(IIIb)

wherein: R^4, R^5, R^8, R^9, R^{10}, $R^{10'}$, R^{11}, R^{12}, R^{13}, R^{14}, $R^{14'}$, R^{16}, R^{18}, R^{19}, X^a, X^b and X^c are as defined in claim 15.

21. The compound according to claim 20, wherein R^4 is selected from: 

,

, 

, 

, 

, 

, 

, 

, 

, 

and 

.

22. The compound according to any one of claims 1 to 21, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is optionally substituted with one or more substituents selected from: halogen, acyl, acyloxy, alkoxy, carboxy, hydroxy, amino, amido, nitro, cyano, azido, alkylthio, thio, sulfonyl, sulfonamido, alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl.

23. The compound according to any one of claims 1 to 21, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is optionally substituted with one or more substituents selected from: halogen, acyl, acyloxy, alkoxy, carboxy, hydroxy, amino, amido, nitro, cyano, azido, alkylthio, thio, sulfonyl and sulfonamido.

24. The compound according to claim 1, wherein the compound is selected from compounds 100 to 168 as set forth in Table 1.

25. A pharmaceutical composition comprising a compound according to any one of claims 1 to 24, and a pharmaceutically acceptable carrier or diluent.

26. A conjugate having Formula (X):

$$T\text{-}[L\text{-}(D)_m]_n$$

(X)

wherein:

T is a targeting moiety;

L is a linker;

D is a compound according to any one of claims 1 to 24;

m is an integer between 1 and 4, and

n is an integer between 1 and 10.

27. A conjugate having Formula (X):

$$T\text{-}[L\text{-}(D)_m]_n$$

(X)

wherein:

T is a targeting moiety;

L is a linker;

m is an integer between 1 and 4;

n is an integer between 1 and 10, and

D is a compound of Formula (IV):



(IV)

wherein:

R^{1a} is selected from: -H, -CH_3, -CHF_2, -CF_3, -F, -Br, -Cl, -OH, -OCH_3, -OCF_3 and -NH_2;

R^{2a} is selected from: -H, -CH_3, -CF_3, -F, -Br, -Cl, -OH, -OCH_3 and -OCF_3;

X is -O-, -S- or -NH-, and R^{4a} is selected from:  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , and  , wherein * is the point of attachment to X, and wherein p is 1, 2, 3 or 4; or

X is O, and R^{4a}-X- is selected from:  ;

R^{5a} is selected from: -C_1-C_6 alkyl, –C_3-C_8 cycloalkyl, –aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{8a} is selected from: -C_1-C_6 alkyl, –C_3-C_8 cycloalkyl and –C_3-C_8 heterocycloalkyl;

each R^{9a} is independently selected from: -C_1-C_6 alkyl, –C_3-C_8 cycloalkyl, –aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl; or R^{9a} is absent and X^b = X;

each R^{10a} is independently selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl, –(C_1-C_6 alkyl)-aryl and  ;

each $R^{10a'}$ is independently selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

each R^{10b} is independently selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{11a} is absent or is -C_1-C_6 alkyl;

R^{12a} is selected from: -C_1-C_6 alkyl, -CO_2R^{8a}, –aryl, -heteroaryl, –(C_1-C_6 alkyl)-aryl, -$S(O)_2R^{16a}$ and  ;

R^{13a} is selected from: -H and -C_1-C_6 alkyl;

R^{14a} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

$R^{14a'}$ is selected from: H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

R^{16a} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{21} is selected from: -C_1-C_6 alkyl, –C_3-C_8 cycloalkyl and –(C_1-C_6 alkyl)-O-R^{5a};

R^{22} and R^{23} are each independently selected from: -H, -halogen, -C_1-C_6 alkyl and -C_3-C_8 cycloalkyl;

R^{24}, R^{25} and R^{26} are each -C_1-C_6 alkyl;

X^a and X^b are each independently selected from: NH, O and S;

X^c is selected from: O, S and $S(O)_2$, and

 denotes the point of attachment to linker, L.

28. The conjugate according to claim 27, wherein R^{1a} is selected from: -CH_3, -CF_3, -OCH_3, -OCF_3 and -NH_2.

29. The conjugate according to claim 27, wherein R^{1a} is selected from: $-CH_3$, $-OCH_3$ and NH_2.

30. The conjugate according to claim 27, wherein R^{2a} is selected from: -H, -F, -Br and -Cl.

31. The conjugate according to any one of claims 27 to 30, wherein X is -O-, -S- or -NH-, and R^{4a} is selected from:  , and  .

32. A conjugate having Formula (X):

$$T\text{-}[L\text{-}(D)_m]_n$$

(X)

wherein:

T is a targeting moiety;

L is a linker;

m is an integer between 1 and 4;

n is an integer between 1 and 10, and

D is a compound of Formula (V):



(V)

wherein:

R^{2a} is selected from: $-CH_3$, $-CF_3$, -F, -Br, -Cl, -OH, $-OCH_3$ and $-OCF_3$;

R^{20a} is selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -(C_1-C_6 alkyl)-O-R^5,  , -CO_2R^8, -aryl, -heteroaryl, –(C_1-C_6 alkyl)-aryl,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  and  ;

R^5 is selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^6 and R^7 are each independently selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -(C_1-C_6 alkyl)-O-R^5, -C_3-C_8 heterocycloalkyl and -C(O)R^{17};

R^8 is selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

each R^9 is independently selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

each R^{10a} is independently selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl, –(C_1-C_6 alkyl)-aryl and  ;

$R^{10a'}$ is selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{11} is selected from: -H and -C_1-C_6 alkyl;

R^{12} is selected from: -H, -C_1-C_6 alkyl, -CO_2R^8, -aryl, -heteroaryl, –(C_1-C_6 alkyl)-aryl, -$S(O)_2R^{16}$ and  ;

R^{13} is selected from: -H and -C_1-C_6 alkyl;

R^{14} and $R^{14'}$ are each independently selected from: -H, C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

R^{16} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{17} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -C_3-C_8 heterocycloalkyl, –(C_1-C_6 alkyl)-C_3-C_8 heterocycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{18} and R^{19} taken together with the N atom to which they are bonded form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from: halogen, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -(C_1-C_6 alkyl)-O-R^5;

R^{24}, R^{25} and R^{26} are each -C_1-C_6 alkyl;

X^a and X^b are each independently selected from: NH, O and S;

X^c is selected from: O, S and $S(O)_2$, and

 denotes the point of attachment to linker, L.

33. The conjugate according to claim 32, wherein R^{2a} is F.

34. The conjugate according to claim 32 or 33, wherein R^{20a} is selected from: -H, -C_1-C_6 alkyl, -(C_1-C_6 alkyl)-O-R^5,  , –(C_1-C_6 alkyl)-aryl,  ,  , and .

35. A conjugate having Formula (X):

$$T\text{-}[L\text{-}(D)_m]_n$$

(X)

wherein:

T is a targeting moiety;

L is a linker;

m is an integer between 1 and 4;

n is an integer between 1 and 10, and

D is a compound of Formula (VI):



(VI)

wherein:

R^{2a} is selected from: -H, $-CH_3$, $-CF_3$, -F, -Br, -Cl, -OH, $-OCH_3$ and $-OCF_3$;

X is -O-, -S- or -NH-, and R^{25} is selected from: $-C_1$-C_6 alkyl, $-(C_1$-C_6 alkyl)-O-R^{5a}, -CO_2R^{8a}, -C(O)-, -aryl, -heteroaryl,$-(C_1$-C_6 alkyl)-aryl,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  and  , wherein * is the point of attachment to X, and wherein p is 1, 2, 3 or 4; or

X is O, and R^{25}-X- is selected from:  ,  and  ;

R^{5a} is selected from: $-C_1$-C_6 alkyl, $-C_3$-C_8 cycloalkyl, –aryl, -heteroaryl and $-(C_1$-C_6 alkyl)-aryl;

R^{6a} is selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

R^{7a} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -(C_1-C_6 alkyl)-O-R^{5a}, -C_3-C_8 heterocycloalkyl and -C(O)R^{17a};

R^{8a} is selected from: -C_1-C_6 alkyl, –C_3-C_8 cycloalkyl and –C_3-C_8 heterocycloalkyl;

each R^{9a} is independently selected from: -C_1-C_6 alkyl, –C_3-C_8 cycloalkyl, –aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl; or R^{9a} is absent and X^b = X;

each R^{10a} is independently selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl, –(C_1-C_6 alkyl)-aryl and  ;

each $R^{10a'}$ is independently selected from: -H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

each R^{10b} is independently selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{11a} is absent or is -C_1-C_6 alkyl;

R^{12a} is selected from: -C_1-C_6 alkyl, -CO_2R^{8a}, –aryl, -heteroaryl, –(C_1-C_6 alkyl)-aryl, -$S(O)_2R^{16a}$ and  ;

R^{13a} is selected from: -H and -C_1-C_6 alkyl;

R^{14a} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

$R^{14a'}$ is selected from: H, -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl and -C_3-C_8 heterocycloalkyl;

R^{16a} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{17a} is selected from: -C_1-C_6 alkyl, -C_3-C_8 cycloalkyl, -C_3-C_8 heterocycloalkyl, –(C_1-C_6 alkyl)-C_3-C_8 heterocycloalkyl, -aryl, -heteroaryl and –(C_1-C_6 alkyl)-aryl;

R^{21} is selected from: -C_1-C_6 alkyl, –C_3-C_8 cycloalkyl and –(C_1-C_6 alkyl)-O-R^{5a};

R^{22} and R^{23} are each independently selected from: -H, -halogen, -C_1-C_6 alkyl and -C_3-C_8 cycloalkyl;

R^{24}, R^{25} and R^{26} are each -C_1-C_6 alkyl;

X^a and X^b are each independently selected from: NH, O and S;

X^c is selected from: O, S and $S(O)_2$, and

 denotes the point of attachment to linker, L.

36. The conjugate according to claim 35, wherein R^{2a} is selected from: $-CH_3$, $-CF_3$, -F, -Br, -Cl, -OH, $-OCH_3$ and $-OCF_3$.

37. The conjugate according to claim 35, wherein R^{2a} is F.

38. The conjugate according to any one of claims 35 to 37, wherein X is -O-, -S- or -NH-, and R^{25} is selected from: $-C_1$-C_6 alkyl, $-(C_1$-C_6 alkyl)-O-R^{5a}, $-(C_1$-C_6 alkyl)-aryl,  ,  ,  ,  ,  ,  ,  ,  and  , or X is O, and R^{25}-X- is selected from:  ,  and  .

39. The conjugate according to any one of claims 35 to 37, wherein X is -O-, -S- or -NH-, and R^{25} is selected from: $-C_1$-C_6 alkyl, $-(C_1$-C_6 alkyl)-O-R^{5a}, $-(C_1$-C_6 alkyl)-aryl,  ,



and

40. The conjugate according to any one of claims 27 to 39, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is optionally substituted with one or more substituents selected from: halogen, acyl, acyloxy, alkoxy, carboxy, hydroxy, amino, amido, nitro, cyano, azido, alkylthio, thio, sulfonyl, sulfonamido, alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl.

41. The conjugate according to any one of claims 27 to 39, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is optionally substituted with one or more substituents selected from: halogen, acyl, acyloxy, alkoxy, carboxy, hydroxy, amino, amido, nitro, cyano, azido, alkylthio, thio, sulfonyl and sulfonamido.

42. The conjugate according to any one of claims 26 to 41, wherein m is 1 or 2.

43. The conjugate according to any one of claims 26 to 42, wherein n is between 2 and 8.

44. The conjugate according to any one of claims 26 to 43, wherein L is a cleavable linker.

45. The conjugate according to claim 44, wherein L is a protease cleavable linker.

46. The conjugate according to claim 44 or 45, wherein L comprises a dipeptide, tripeptide or tetrapeptide.

47. The conjugate according to any one of claims 26 to 46, wherein T binds to a tumor associated antigen.

48. The conjugate according to any one of claims 26 to 47, wherein T is an antibody or antigen-binding antibody fragment.

49. The conjugate according to claim 48, wherein the antibody is a bispecific or multispecific antibody.

50. A pharmaceutical composition comprising a conjugate according to any one of claims 26 to 49, and a pharmaceutically acceptable carrier or diluent.

51. A compound according to any one of claims 1 to 24 or a conjugate according to any one of claims 26 to 49 for use in therapy.

52. A compound according to any one of claims 1 to 24 or a conjugate according to any one of claims 26 to 49 for use in the treatment of cancer, an autoimmune disease or a viral infection.

53. Use of a compound according to any one of claims 1 to 24 or a conjugate according to any one of claims 26 to 49 in the manufacture of a medicament for the treatment of cancer, an autoimmune disease or a viral infection.